Browse > Article
http://dx.doi.org/10.5352/JLS.2011.21.11.1652

Characteristics of Hematopoitic Growth Factor, G-CSF and Its Clinical Vision  

Park, Jeong-Hae (Department of Clinical Laboratory Science, Dong Eui University)
Park, Jung-Ae (Department of Clinical Laboratory Science, Dong Eui University)
Kang, Seok-Woo (Department of Agricultural Biology, National Academy of Agricultural Science, RDA)
Goo, Tae-Won (Department of Agricultural Biology, National Academy of Agricultural Science, RDA)
Chung, Kyung-Tae (Department of Clinical Laboratory Science, Dong Eui University)
Publication Information
Journal of Life Science / v.21, no.11, 2011 , pp. 1652-1657 More about this Journal
Abstract
The production of blood cells is regulated by more than 20 different growth factors, called hematopoitic growth factors. These factors have been produced in prokaryotic and mammalian systems for their clinical use. Glranulocyte-Colony Stimulating Factor (G-CSF) is an important therapeutic factor for cancer patients as well as patients with congenital conditions. These patients do not have enough neutrophils and have a high risk of infection. Two groups of recombinant G-CSF have been used to specially treat cancer patients after chemotherapy because chemotherapy induces neutropenia, a major side effect of chemotherapy drugs. Here, structural and biological characteristics of G-CSF are presented. In addition, the relationship between chemotherapy and neutropenia, which is a severe reduction of neutrophils in the blood, and clinical application of G-CSF is discussed. Recombinant G-CSFs are grouped in two forms. Non-glycosylated G-CSF, filgrastim, is produced in Escherichia coli and glycosylated G-CSF, lenograstim, is produced in Chinese hamster ovary cells. Differences in structure and biological activity are compared and challenges for biosimilar production are also highlighted.
Keywords
G-CSF; chemotherapy; filgrastim; lenograstim; biosimilar;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Scrip Report. 2007. Biosimilar, Biogenerics and Follow-on Biologics. Informa UK Ltd. (http://www.scripintelligence.com/multimedia/archive/00000/BS1342_117a.pdf)
2 Smith, L., C. Redfield, J. Boyd, G. Lawrence, R. Edwards, R. Smith, and C. Dobson. 1992. Human interleukin 4. The solution structure of a four-helix bundle protein. J. Mol. Biol. 224, 899-904.   DOI
3 Sourgens, H. and F. Lefrere. 2011. A systematic review of available clinical evidence-filgrastim compared with lenograstim. Int. J. Clin. Pharmacol. Ther. 49, 510-518.   DOI
4 Nissen, C. 1994. Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. Eur. J. Cancer 30A, S12-14.
5 Oh-eda, M., M. Hasegawa, K. Hattori, H. Kuboniwa, T. Kojima, T. Orita, K. Tomonou, T. Yamazaki, and N. Ochi. 1990. O-linked sugar chain of human granulocyte colony- stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. J. Biol. Chem. 265, 11432-11435.
6 Ono, M., M. Oh-eda, S. Kamachi, M. Kato, Y. Endo, and N. Ochi. 1992. Structure of G-CSF: significance of the sugar chain. J. Nutr. Sci. Vitaminol. (Tokyo) Spec No, 337-340.
7 Ono, M. 1994. Physicochemical and biochemical characteristics of glycosylatedrecombinant human granulocyte colony stimulating factor (lenograstim). Eur. J. Cancer 30A, S7-11.
8 Pandit, J., A. Bohm. J. Jancarik, R. Halenbeck, K. Koths, and S. Kim. 1992. Three-dimensional structure of dimeric human recombinant macrophage colony-stimulating factor. Science 258, 1358-1362.   DOI
9 Parham, P. 2009. The Immune system, 3 eds, Garland Science, New York, NY.
10 Procopio, G., M. Niger, and I. Testa. 2011. Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. Neurol. Sci. [Epub ahead of print].
11 Ria, R., T. Gasparre, G. Mangialardi, A. Bruno, G. Iodice, A. Vacca, and F. Dammacco. 2010. Comparison between filgrastim and lenograstim plus chemotherapy for mobilization of PBPCs. Bone Marrow Transplant 45, 277-281.   DOI   ScienceOn
12 Keating, G. 2011. Lenograstim: a review of its use in chemotherapy- induced neutropenia, for acceleration of neutrophil recovery following haematopoietic stem cell transplantation and in peripheral blood stem cell mobilization. Drugs 71, 679-707.   DOI   ScienceOn
13 Crawford, J., D. Dale, and G. Lyman. 2004. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228-237.   DOI   ScienceOn
14 Brandt, S., W. Peters, S. Atwater, J. Kurtzberg, M. Borowitz, R. Jones, E. Shpall, R. Bast, Jr, C. Gilbert, and D. Oette. 1988. Effect of recombinant human granulocyte-macrophage colony- stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N. Engl. J. Med. 318, 869-876.   DOI   ScienceOn
15 Cooper, K., J. Madan, S. Whyte, M. Stevenson, and R. Akehurst. 2011. Granulocyte colony-stimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and meta-analysis. BMC Cancer 11, 404.   DOI
16 Cowling, G. and T. Dexter. 1992. Erythropoietin and myeloid colony stimulating factors. Trends Biotechnol. 10, 349-357.   DOI
17 Diederichs, K., S. Jacques, T. Boone, and P. Karplus. 1991. Low-resolution structure of recombinant human granulocyte- macrophage colony stimulating factor. J. Mol. Biol. 221, 55-60.   DOI
18 Gervais, V., A. Zerial, and H. Oschkinat. 1997. NMR investigations of the role of the sugar moiety in glycosylated recombinant human granulocyte-colony-stimulating factor. Eur. J. Biochem. 247, 386-395.   DOI   ScienceOn
19 Hill, C., T. Osslund, and D. Eisenberg. 1993. The structure of granulocyte-colony-stimulating factor and its relationship to other growth factors. Proc. Natl. Acad. Sci. USA 90, 5167-5171.   DOI   ScienceOn
20 Hoglund, M. 1998. Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference? Med. Oncol. 15, 229-233.   DOI
21 Walter, M., W. Cook, B. Zhao, R. Jr. Cameron, S. Ealick. R. Jr. Walter, P. Reichert, T. Nagabhushan, P. Trotta, and C. Bugg. 1992. Crystal structure of recombinant human interleukin- 4. J. Biol. Chem. 267, 20371-20376.
22 Sorgel, F., H. Lerch, and T. Lauber. 2010. Physicochemical and biologic comparability of a biosimilar granulocyte colony- stimulating factor with its reference product. BioDrugs 24, 347-357.   DOI   ScienceOn
23 Souza, L., T. Boone, J. Gabrilove, P. Lai, K. Zsebo, D. Murdock, V. Chazin, J. Bruszewski, H. Lu, K. Chen, J. Barendt, E. Platzer, M. Moore, R. Mertelsmann, and K. Welte. 1986. Recombinant human granulocyte colony-stimulating factor: effects on normal and leukemic myeloid cells. Science 232, 61-65.   DOI
24 Wadhwa, M., C. Bird, M. Hamill, A. Heath, P. Matejtschuk, and R. Thorpe. 2011. The 2nd International Standard for human granulocyte colony stimulating factor. J. Immunol. Methods 367, 63-69.   DOI
25 Zink, T., A. Ross, K. Luers, C. Cieslar, R. Rudolph, and T. Holak. 1994. Structure and dynamics of the human granulocyte colony-stimulating factor determined by NMR spectroscopy. Loop mobility in a four-helix-bundle protein. Biochemistry 33, 8453-8463.   DOI   ScienceOn
26 Zsebo, K., A. Cohen, D. Murdock, T. Boone, H. Inoue, V. Chazin, D. Hines, and L. Souza. 1986. Recombinant human granulocyte colony stimulating factor: molecular and biological characterization. Immunobiology 172, 175-184.   DOI
27 Nagata, S., M. Tsuchiya, S. Asano, Y. Kaziro, T. Yamazaki, O. Yamamoto, Y. Hirata, N. Kubota, M. Oheda, and H. Nomura. 1986. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 319, 415-418.   DOI   ScienceOn
28 Nagata, S., M. Tsuchiya, S. Asano, O. Yamamoto, Y. Hirata, N. Kubota, M. Oheda, H. Nomura, and T. Yamazaki. 1986. The chromosomal gene structure and two mRNAs for human granulocyte colony-stimulating factor. EMBO J. 5, 575-581.
29 Klumpp, T., K. Mangan, S. Goldberg, E. Pearlman, and J. Macdonald. 1995. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J. Clin. Oncol. 13, 1323-1327.
30 Kindt, T., R. Goldsby, B. Osborne, and J. Kuby. 2007. The Immune System. 6th eds. Chapter 2. W.H. Freeman, New York, NY.
31 Kuderer, N., D. Dale, J. Crawford, L. Cosler, and G. Lyman. 2006. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106, 2258-2266.   DOI   ScienceOn
32 Lieschke, G., D. Grail, G. Hodgson, D. Metcalf, E. Stanley, C. Cheers, K. Fowler, S. Basu, Y. Zhan, and A. Dunn. 1994. Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 84, 1737-1746.
33 Lu, H., C. Clogston, L. Narhi, L. Merewether, W. Pearl, and T. Boone. 1992. Folding and oxidation of recombinant human granulocyte colony stimulating factor produced in Escherichia coli. Characterization of the disulfide-reduced intermediates and cysteine-serine analogs. J. Biol. Chem. 267, 8770-8777.
34 Martin-Christin, F. 2001. Granulocyte colony stimulating factors: how different are they? How to make a decision? Anticancer Drugs 12, 185-191.   DOI   ScienceOn
35 McQuaker, I., A. Hunter, S. Pacey, A. Haynes, A. Iqbal, and N. Russell. 1997. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with ymphoproliferative disorders: evidence for clinical and economic benefit. J. Clin. Oncol. 15, 451-457.
36 Anderlini, P. 2009. Effects and safety of granulocyte colony- stimulating factor in healthy volunteers. Curr. Opin. Hematol. 16, 35-40.   DOI   ScienceOn
37 Hughes, W., D. Armstrong, G. Bodey, E. Bow, A. Brown, T. Calandra, R. Feld, P. Pizzo, K. Rolston, J. Shenep, and L. Young. 2002. Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin. Infect. Dis. 34, 730-751.   DOI   ScienceOn
38 Aapro, M., J. Bohlius, D. Cameron, L. Dal Lago, J. Donnelly, N. Kearney, G. Lyman, R. Pettengell, V. Tjan-Heijnen, J. Walewski, D. Weber, and C. Zielinski. 2011. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy- induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur. J. Cancer 47, 8-32.